Biotechnology

Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153 Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for t...

2025-10-23 04:00 1301

SynbioTech Brings Taiwan's Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging

LAS VEGAS, Oct. 22, 2025 /PRNewswire/ -- In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company fromTaiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically proven strain, which w...

2025-10-23 00:00 1278

Visionary Holdings Launches Toronto-Based Joint Venture to Drive Global Commercialization of Innovative Stem Cell Therapy for Diabetes Remission, Targeting a $150 Billion Market Opportunity

TORONTO, Oct. 22, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced the signing of a strategic cooperation agreement with Jiangsu Yike Regenerative Medical Technology Co., Ltd. ("Yike")...

2025-10-22 21:30 2585

Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma

SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today announced that theBlood published the latest result...

2025-10-22 19:39 1218

LISCure BioSciences Secures World's First Approval for "Joint Health Probiotic" as Recognized Health Functional Ingredient

SEOUL, South Korea, Oct. 22, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") announced that its proprietary joint health probiotic, JointWorks®, has been officially approved by the Korean Ministry of Food and Drug Safety (MFDS) as Recognized Health Functional Ingredient. This approval marks...

2025-10-22 14:28 993

Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology

TOKYO, Oct. 22, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku,Tokyo; "Renalys") is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for Pediatric Nephrology (Head Office: Chiyoda-ku,Tokyo). T...

2025-10-22 14:00 862

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM's propriet...

2025-10-22 14:00 1835

ACROBiosystems and Partners Conclude OrganoAsia 2025

ACROBiosystems and Partners Conclude OrganoAsia 2025 - Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization TOKYO, Oct. 10, 2025 /PRNewswire/ -- ACROBiosystems, together with Leica Biosystems, Molecular Devices, and Leica Microsystem...

2025-10-22 11:03 1994

ACROBiosystems and Partners Conclude OrganoAsia 2025

In the news release, ACROBiosystems and Partners Conclude OrganoAsia 2025, issued10-Oct-2025 by ACROBiosystems Group over PR Newswire, "Tokyo University of Science" in the paragraph starting with "The conference gathered leading specialists such as..." should read "Institute of Science Tokyo"....

2025-10-22 11:01 1832

WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index

* The only company from pharmaceutical industry selected for inclusion in the Index * Also included in HSI ESG Index and Hang Seng ESG 50 Index * Green CRDMO solution provider with outstanding sustainability performance HONG KONG, Oct. 21, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a lea...

2025-10-22 08:30 934

HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101

TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US patent (Patent No. 12,447,195) by the United States Patent and Trademark Office (USPTO). Titled"E...

2025-10-21 19:00 1014

Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy

TAIPEI and SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant's biological artificial intelligence (AI) system. DeepMind re...

2025-10-21 10:49 970

SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform

SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization. SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and co...

2025-10-21 09:20 1155

NSG Bio Launches NSG BioSuites at Geneo - A New Product, Largest Site, and Fourth Location in Singapore

SINGAPORE, Oct. 21, 2025 /PRNewswire/ -- NSG Bio, a leading provider of flexible and high-quality biotech laboratory spaces, announced the launch of its latest product, NSG BioSuites, located at the brand-new Geneo development in Singapore Science Park. This marks NSG Bio's fourth site in Singapor...

2025-10-21 08:00 961

LabConnect Featured in Season Finale of Emmy-Nominated Series Tomorrow's World Today

JOHNSON CITY, Tenn., Oct. 21, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central laboratory and support services for clinical trials, will be featured on the season 9 finale of the innovation-focused TV series, Tomorrow's World Today. Premiering on Science Channel on November 8,...

2025-10-21 01:11 943

Benchling Partners with Anthropic to Build a Bridge Between Science and AI

Claude's Life Sciences Ecosystem pairs Benchling AI with advanced reasoning in Claude SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- Benchling today announced a partnership with ...

2025-10-21 00:00 1068

Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London

PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future of one of the fastest-growing fields in emerging medicine....

2025-10-20 19:43 874

HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025

Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stag...

2025-10-20 19:00 1226

Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington's Disease Treatment

SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- The research team led by Dr. Yuejun Chen , founder of UniXell Biotech, published online an article titled "3D-Cultured Human Medium Spiny Neurons Achieve Functional Integration into Huntingtin Disease Mouse Neural Circuits and Improve Motor Deficits" in the ...

2025-10-20 18:13 832

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

* After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). * OS was significantly longer with sac-TMT than with chemotherapy (H...

2025-10-20 17:06 1181
1 ... 891011121314 ... 341